Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Inclusion Criteria: * Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening * Males or females aged 20-80 years * Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months * Body mass index ≥ 23 kg/m² * Estimated glomerular filtration ratio (eGFR) ≥ 60 ml/min/1.73m² Exclusion Criteria: * Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes * Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit * Pregnant or breastfeeding patients, or patients not using contraception. Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 times the upper limit of normal) * Patients with heart failure or a history of heart failure * Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer) * Patients who have participated in another clinical study within the last 30 days * Alcohol addiction * Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated * Patients taking other oral hypoglycemic agents or insulin or other investigational drugs * Patients deemed unsuitable for the study based on the investigator's judgment